This EVERSANA white paper examines the rapid growth of China’s light medical aesthetics market, driven by increasing consumer demand for minimally invasive cosmetic procedures, particularly among younger individuals. It focuses on injectable treatments such as hyaluronic acid, botulinum toxin, and regenerative injections, outlining their applications, market dynamics, regulatory requirements, competitive landscape, and future trends. The paper highlights the shift from surgical to non-surgical procedures due to their lower risk, shorter recovery time, and repeat treatment potential. It concludes that continued innovation, stricter regulation, physician training, and consumer education will drive broader adoption of safer, more effective injectable aesthetic treatments in China.

Join for free to read